Germline SDHB and SDHD Mutations in Pheochromocytoma and Paraganglioma Patients by Huang, Yiqiang et al.
Philadelphia College of Osteopathic Medicine
DigitalCommons@PCOM
PCOM Scholarly Papers
10-1-2018
Germline SDHB and SDHD Mutations in
Pheochromocytoma and Paraganglioma Patients
Yiqiang Huang
Lin-Ang Wang
Qiubo Xie
Jian Pang
Luofu Wang
See next page for additional authors
Follow this and additional works at: https://digitalcommons.pcom.edu/scholarly_papers
Part of the Endocrine System Diseases Commons
This Article is brought to you for free and open access by DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Scholarly Papers by
an authorized administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.
Recommended Citation
Huang, Yiqiang; Wang, Lin-Ang; Xie, Qiubo; Pang, Jian; Wang, Luofu; Yi, Yuting; Zhang, Jun; Zhang, Yao; Chen, Rongrong; Lan,
Weihua; Zhang, Dianzheng; and Jiang, Jun, "Germline SDHB and SDHD Mutations in Pheochromocytoma and Paraganglioma
Patients" (2018). PCOM Scholarly Papers. 1958.
https://digitalcommons.pcom.edu/scholarly_papers/1958
Authors
Yiqiang Huang, Lin-Ang Wang, Qiubo Xie, Jian Pang, Luofu Wang, Yuting Yi, Jun Zhang, Yao Zhang,
Rongrong Chen, Weihua Lan, Dianzheng Zhang, and Jun Jiang
This article is available at DigitalCommons@PCOM: https://digitalcommons.pcom.edu/scholarly_papers/1958
 Germline SDHB and SDHD Mutations in Pheochromocytoma 1 
and Paraganglioma Patients 2 
Yiqiang Huang
1
, Linang Wang
1
, Qiubo Xie
1
, Jian Pang
1
, Luofu Wang
1
, Yuting Yi
2
, Jun 3 
Zhang
1
, Yao Zhang
1
, Rongrong Chen
2
, Weihua Lan
1
,
 
Dianzheng Zhang
3
,
 
and Jun 4 
Jiang
1*
 5 
1
Department of Urology, Institute of Surgery Research, Daping Hospital, Third Military 6 
Medical University, Chongqing 400042, PR China; 
2
Geneplus-Beijing Institute, Beijing 7 
102206, PR China； 3Department of Bio-Medical Sciences, Philadelphia College of 8 
Osteopathic Medicine, 4170 City Ave., Philadelphia, PA 19131 9 
 10 
 11 
Running title: SDH Gene Mutations in PCC/PGL 12 
 13 
*Corresponding author: 14 
Jun Jiang  15 
10#, Changjiang Zhilu, Yuzhong District, Chongqing 400042, PR China 16 
Tel: +86-023-68757946 17 
Fax: +86-023-68757946; 18 
Email: jiangjun_64@163.com 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
Page 1 of 23 Accepted Manuscript published as EC-18-0325.R1. Accepted for publication: 04-Oct-2018
Copyright © 2018 the authors Downloaded from Bioscientifica.com at 11/06/2018 06:44:32PM
via Philadelphia College of
 27 
Abstract 28 
Pheochromocytoma and paragangliomas (PCC/PGL) are neuroendocrine tumors that arise from chromaffin 29 
cells of the adrenal medulla and sympathetic/parasympathetic ganglia, respectively. Of clinical relevance 30 
regarding diagnosis is the highly variable presentation of symptoms in PCC/PGL patients. To date, the 31 
clear-cut correlations between the genotypes and phenotypes of PCC/PGL have not been entirely 32 
established. In this study, we reviewed the medical records of PCC/PGL patients with pertinent clinical, 33 
laboratory and genetic information. Next-generation sequencing (NGS) performed on patient samples 34 
revealed specific germline mutations in the SDHB (succinate dehydrogenase complex iron-sulfur subunit 35 
B) and SDHD（succinate dehydrogenase complex subunit D ) genes and these mutations were validated by 36 
Sanger sequencing. Of the 119 patients, two were identified with SDHB mutation and one with SDHD 37 
mutation. Immunohistochemical (IHC) staining was used to analyze the expression of these mutated genes. 38 
The germline mutations identified in the SDH genes were: c343C>T and c.541-542A>G in the SDHB gene 39 
and c.334-337delACTG in the SDHD gene. IHC staining of tumors from the c.343C>T and c.541-2A>G 40 
carriers showed positive expression of SDHB. Tumors from the c.334-337delACTG carrier showed no 41 
expression of SDHD and a weak diffused staining pattern for SDHB. We strongly recommend genetic 42 
testing for suspected PCC/PGL patients with a positive family history, early onset of age, erratic 43 
hypertension, recurrence or multiple tumor sites and loss of SDHB and/or SDHD expression. Tailored 44 
personal management should be conducted once a patient is confirmed as an SDHB and/or SDHD 45 
mutation carrier or diagnosed with PCC/PGL. 46 
Keywords:  PCC/PGL; SDHB; SDHD; Genotype-phenotype correlation 47 
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1. Introduction 50 
Pheochromocytomas/Paragangliomas (PCC/PGLs) are tumors, arose from neural crest-derived chromaffin 51 
cells, produce and secrete catecholamines [1-3]. PCCs are tumors of the adrenal medulla and PGLs 52 
originate from sympathetic (e.g. organ of Zuckerkandl) or parasympathetic (e.g. carotid body) paraganglia. 53 
The incidence of PCC/PGL is up to 8 per 100,000 with its peak onset around the 4th decade of lives [4-6]. 54 
Most PCC/PGLs are benign but with high morbidity and mortality due to hypersecretion of catecholamines 55 
and metanephrines, which induce hypertension and cardiovascular diseases. It is estimated that ~30%  56 
PCC/PGLs are genetically inherited disease and this percentage may rise as new PCC/PGL-causing 57 
mutations are being identified. 58 
Succinate dehydrogenase (SDH) is a protein complex involving in both citric acid cycle and respiratory 59 
electron transfer chain reactions [7]. The SDH complex comprises two anchoring subunits SDHC 60 
(succinate dehydrogenase subunit C) and SDHD and two catalytic subunits SDHA (succinate 61 
dehydrogenase complex flavoprotein subunit A) and SDHB. SDHB, an 8-exon gene localized on 62 
chromosome 1p36.13 and part of the mitochondrial electron transport complex II, is the most commonly 63 
mutated subunit in hereditary forms of PCC/PGLs. SDHD, the 4-exon gene positioned on chromosome 64 
11q23, is another member of the SDH complex [8]. If any component of the SDH complex is lost, SDHB 65 
IHC becomes negative [9]. Loss of SDHB by immunohistochemistry (IHC) in PCC/PGL is strongly 66 
correlated with SDH subunit gene mutation. So far, SDH deficiency has been observed in PCC/PGLs, 67 
gastrointestinal stromal tumors, pancreatic neuroendocrine tumor, renal carcinoma, pituitary adenoma and 68 
pulmonary chondroma [9, 10]. 69 
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The Cancer Genome Atlas (TCGA) molecular taxonomy divides PCC/PGL into four main clusters: 70 
pseudohypoxia, Wnt-signaling, kinase-signaling and cortical mixture [11]. The pseudohypoxia group can 71 
be divided into at least two subgroups. The tricarboxylic acid (TCA) cycle-related subgroup contains 72 
germline mutations in succinate dehydrogenase subunits SDHA, SDHB, SDHC, SDHD as well as 73 
succinate dehydrogenase complex assembly factor 2 (SDHAF2), FH (fumarate hydratase)，MDH2 (malate 74 
dehydrogenase 2) and GOT2 (Glutamic-Oxaloacetic Transaminase 2) [12, 13]. The VHL/HIF2A-related 75 
subgroup shows both somatic and germline mutations [13]. Germline mutations in SDH gene are 76 
responsible for 6% to 9% of sporadic PCC/PGLs, 29% of pediatric cases, 38% of malignant tumors and 77 
more than 80% of familial aggregations of PGL and PCC [14]. Germline mutations in the SDHB gene are 78 
associated with hereditary paraganglioma syndrome type 4 (PGL4), while germline mutations of SDHD 79 
are present in hereditary paraganglioma syndrome type 1 (PGL1). The penetrance in SDHB and SDHD 80 
mutation-positive non-probands by age 60 years was only 21.8% and 43.2%, respectively [15]. 81 
Furthermore, maternal transmission and genomic imprinting in SDHD could mask the hereditary nature of 82 
paraganglioma in rare cases [16]. The difficulty of making a precise diagnosis delays appropriate treatment. 83 
Thus, hereditary PCC/PGL poses a significant challenge to clinicians.  84 
Although the genetic basis of PCC/PGL is well characterized, the cancer-driving mutations for all 85 
PCC/PGL remain unknown. Here, we report the identification of a nonsense mutation and a splice site 86 
mutation in the SDHB gene and an SDHD frameshift mutation by genetic screening and 87 
immunohistochemistry.  88 
 89 
 90 
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2. Materials and Methods 92 
2.1 Patients and Genetic Testing 93 
The Institutional Review Board of Daping Hospital of the Third Military Medical University approved this 94 
study. Written informed consents were obtained from the patients for use of their medical records and 95 
related images. A total of 119 PCC/PGL patients were diagnosed and underwent resection of their tumors 96 
in our institute between 2011 and 2018. The diagnoses were confirmed by three licensed pathologists 97 
based on H&E stained tumor specimens (Fig.1) and tumor-specific expression of CgA (Chromogranin A ), 98 
Syn (Synaptophysin), CD56 (Neural Cell Adhesion Molecule 1), S-100 (S100 Calcium Binding Protein B), 99 
CK (Choline Kinase Beta), MelanA (Protein Melan-A), HMB45 (Melanoma Marker Antibody), CD34 100 
(CD34 Molecule), SMA (survival of motor neuron 1, telomeric), and Ki-67 (Proliferation Marker Protein 101 
Ki-67) (data not shown). For the genetic testing study, inclusion criteria consisted of the early age of onset, 102 
extra renal lesions, bilateral adrenal gland lesions, positive family history, recurrent or multifocal disease. 103 
To conduct Target Capture-Based Deep Sequencing (BGI Health, Shenzhen, Guangdong, China), total 104 
DNA isolated from peripheral blood cells of the patients was used to screen for potential mutations in the 105 
following genes: SDHAF2, SDHB, SDHC, SDHD, MAX (MYC associated factor X), NF1 (neurofibromin 106 
1), RET (Ret Proto-Oncogene), VHL (Von Hippel-Lindau), and TMEM127 (Transmembrane Protein 127). 107 
Upon identification of the mutations, Sanger sequencing was conducted on DNA of the probands’ family 108 
members to identify the specific mutation. Of these patients, 3 with SDHB or SDHD mutations; 21 in 5 109 
families with VHL mutations; 10 in 4 families with RET mutations and 1 with somatic HIF2A, which has 110 
been described in our previous study [17-19]. 111 
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2.2 Immunohistochemistry 112 
Immunohistochemical (IHC) staining was performed as described previously [9, 17, 20, 21]. In brief, the 113 
tumor specimens were retrieved from the Department of Pathology of Daping hospital and IHC staining 114 
was performed on formalin-fixed paraffin-embedded tissues. The sections were deparaffinized and heat 115 
antigen retrieved using a citric acid buffer. The antibodies against SDHB (1:200, Proteintech, Rosemont, 116 
IL, USA; catalog number: 10620-1-AP) and SDHD (1:200, Bioss, Beijing, China; catalog 117 
number: ab08187596; immunogen range: 81-159 amino acid residue) were used. The HRP-labeled 118 
secondary goat anti-rabbit antibody was purchased from EnVisio Detection Systems (Dako, Glostrup, 119 
Denmark). A peroxidase-labeled polymer was conjugated to immunoglobulins (DAKO) with 3, 120 
3-diaminobenzidine as a chromogen. The GIST（gastrointestinal stromal tumor） tissues were stained and 121 
served as an external positive control[9]. 122 
123 
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3. Results 124 
3.1 Clinical characteristics 125 
Of the 119 cases, 90 (75.6 %) developed unilateral neoplasia, 10 (8.4 %) developed bilateral tumors, 10 126 
(8.4%) located in bladder, two in carotid body, two in duodenum and one in cerebellum, ear, mediastinum, 127 
pleura, rectum, respectively. Of note, four patients (3.4 %) presented with malignant PCC/PGL. Among all 128 
the patients, three were identified with SDHx mutations.  129 
Proband 1 was a 14-year-old boy. With blurred vision, intermittent headache, and high blood pressure 130 
(208/156 mmHg), he was diagnosed as hypertensive retinopathy in November 2011. His VMA level was 131 
approximately two times of the normal level (72µmol/24h urine; normal level < 35µmol/24h urine) (Table 132 
1). Although craniocerebral MRI revealed no abnormalities, ultrasonography results suggest thyroid 133 
nodules and hypertensive heart disease. Enhanced CT scans of the thorax and abdomen revealed a 134 
5.1×3.4cm post-caval mass in the upper part of the abdomen (Fig.2 A and D). He underwent a tumor 135 
resection in November 2011 after taking oral alpha-receptor inhibitors for two weeks. Results from 136 
histopathologic examination of the tumor suggest he had a paraganglioma. His blood pressure became 137 
normal three days after tumor resection. Enhanced CT scanning of the thorax, abdomen and pelvic cavities 138 
showed no recurrence or metastasis. His blood pressure became normal in all the follow-ups and the last 139 
one was in August 2017. Briefly, in proband 1’s family, his father died of a stroke at age of 32. His mother 140 
was conducted with Sanger sequencing, but no mutation was identified. His only uncle has hypertension. 141 
Therefore, we speculated that the mutation of the proband was inherited from his father. Other family 142 
members showed no evidence of PCC/PGL. 143 
Proband 2 was a 32-year-old male admitted to our hospital with a history of hypertension for three years. 144 
His blood pressure was 160/100mmHg at diagnosis. Physical examination found no abnormalities. 145 
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Laboratory test showed an elevated urine norepinephrine 1890 µg/L (normal range:10～70µg/L). MRI 146 
scans showed a 3×2cm para-aortic mass in the middle of his abdomen (Fig.2 B and E). Laparoscopic 147 
surgery was attempted initially, but ultimately open surgery was required to remove the mass in December 148 
of 2017. Pathological examination of the mass revealed a paraganglioma. His blood pressure became 149 
normal ten days after the surgery. In proband 2’s family, the father has hypertension for many years, and 150 
the mother did not have any abnormality. MRI or CT scan showed no evidence of PCC/PGL. The other 151 
family members refused referrals for further medical examination.  152 
Proband 3 was a 45-year-old female with intermittent dizziness, palpitation, and nausea for one year. 153 
History showed that a PGL located in the region of the right jugular foramen was diagnosed five years ago 154 
and resected at the West China Hospital (Sichuan Province, China). Hyperthyroidism was diagnosed two 155 
years ago. Enhanced CT scans revealed a 2.7×2.9 cm mass located at the bifurcation of the abdominal 156 
aorta (Fig.2 C and F). Laboratory tests revealed no abnormalities. She underwent laparoscopic tumor 157 
resection on December 12, 2014. Pathological examination revealed a paraganglioma. After surgery, her 158 
blood pressure returned to normal without medication. CT scans from the neck to pubic regions on her last 159 
follow up in August of 2016 revealed no lesion. Proband 3’s parents and her two children showed no sign 160 
of PGLs and refused to be conducted with Sanger sequencing. 161 
3.2 Identification of mutations in the SDHB and SDHD genes 162 
We identified two heterozygous germline mutations in the SDHB gene: c.343C>T in proband 1 (Fig. 3A) 163 
and c.541-2A>G in proband 2 (Fig. 3B). In addition, a frame-shift variant (c.334_337delACTG，164 
p.Asp113Metfs*21) in exon 4 of the SDHD gene was detected in proband 3 (Fig. 3 C). In addition, we 165 
identified a somatic point mutation in the SRD5A2 gene (c.578A>G) in proband 2. Of note, all the 166 
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mutations were further confirmed by Sanger sequencing. There was no mutation in the remaining 167 
susceptibility gene panel.  168 
3.3 Expression of the mutated SDHB and SDHD  169 
Since multiple lines of evidence indicate that IHC staining of SDHB is a robust and reliable surrogate 170 
marker for SDH gene mutations [9, 20-24], we conducted IHC of SDHB on all the tumor tissues. Positive 171 
expression of SDHB was observed using IHC staining in proband 1-derived tumor tissues that harbor the 172 
c.343C>T SDHB gene mutation (Fig. 4, B). Expression of the c.541_2A>G SDHB mutant allele (proband 173 
2) in PGL cells and surrounding endothelial and inflammatory cells revealed a distinct cytoplasmic 174 
granular staining pattern (Fig. 4, C). Tissue samples of proband 3 (c.334_337delACTG mutation) were 175 
negative for SDHD (Fig. 4, H) and showed weak diffused SDHB staining (Fig. 4, D).   176 
4. Discussion 177 
The literature search identified a total of eight reports with thirteen c.343C>T mutation carriers in eight 178 
families [1, 4, 25-30]. Of which, Ivana Jochmanova reported the c.343C>T as a function affected mutation; 179 
van Hulsteijn, L. T. et.al reported the c.343C>T as a pathologic mutation which leads to malignant PGL 180 
with bone metastasis. In this study, we found this mutation caused an early onset of disease with a broad 181 
profile of clinical manifestations. Although the c.343C>T mutation results in the replacement of an 182 
arginine by a termination codon (p.Arg115Ter), IHC staining the showed positive SDHB in the tumor from 183 
the the14-year-old boy (Fig. 4, B). This is consistent with previous studies showing that this nonsense 184 
mutation produces a truncated protein of less than half the full-length protein of 280 amino acids [1, 25]. A 185 
recent nationwide study of 194 SDHB mutation carriers found the prevalence of c.343C>T mutation is 186 
about 1.5 % (3/194; 1 with PCC and 2 with PGLs) [30], suggesting that this mutation is likely to be 187 
Page 9 of 23 Accepted Manuscript published as EC-18-0325.R1. Accepted for publication: 04-Oct-2018
Copyright © 2018 the authors Downloaded from Bioscientifica.com at 11/06/2018 06:44:32PM
via Philadelphia College of
underestimated.  188 
Since Timmers et al. first reported the c.541-2A>G mutation in 2007 [26], five additional reports have 189 
documented the same mutation. Four probands showed a positive family history of PCC/PGLs, and three 190 
had affected relatives while one presented with metastases [1, 26, 31-33]. Noticeably, an infant carrier was 191 
diagnosed with leukoencephalopathy without PCC/PGL[33]; a 19-year-old female carrier was diagnosed 192 
with hereditary oncolytic renal cancer [31] and an 11-year-old boy was diagnosed with polycythemia and 193 
abdominal PGL [32]. In 2017, our team reported a case with a HIF2A somatic mutation-induced 194 
polycythemia and PCC and a case of HIF2A germline–mutation induced polycythemia in a patient with 195 
VHL-associated renal cell carcinoma [17, 34]. It is likely for this reason that the pseudohypoxia-related 196 
PCC/PGL is fundamentally a metabolic disease. In our study, the expression of SDHB was similar to the 197 
external positive control (Fig. 4, C). This is most likely due to the fact that the primary antibody targets 198 
only the amino acids present on the truncated protein. Therefore, antibodies specifically against the 199 
full-length, the N-terminal or C-terminal portions should be used in future studies. It seems that the 200 
c.541-2A>G carriers had a higher penetrance, early onset, more severe and complicated phenotypes, which 201 
warrants further investigation. 202 
Though more than 130 unique SDHD gene mutations have been reported in hereditary PGL1 [35], only 203 
two studies listed the c.334_337delACTG variant as we report here [4, 36]. Amar et al. reported the 204 
c.334_337delACTG mutant in a sporadic carrier and a syndromic or familial carrier [36], while Benn et al. 205 
reported two carriers of this mutant in a family with PCC, an abdominal PGL and HNPGL [4]. Since none 206 
of these groups investigated the expression of this mutated gene, we are the first to study the expression of 207 
SDHD and SDHB in the c.334-337delATCG carrier. The results showed a weak and diffused SDHB 208 
staining pattern and with negative staining for SDHD (Fig. 4, D and H). A previous study suggests that a 209 
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weak-diffused pattern of SDHB may have a stronger correlation with mutations in SDHD rather than 210 
SDHB [37]. Based on the findings in our study, c.334_337delATCG in the SDHD gene appeared to affect 211 
SDHB expression and thus linked to a more grievous phenotype（simultaneous PCC and PGL lesions). In 212 
addition, the adjacent mutation (c.337_340delGACT) has the same amino acid change (p.Asp113Metfs*21) 213 
with our case, which may indicate it is a hotspot mutation region.  214 
PCC/PGL present as solitary lesions in 90–95% of cases [38]. SDHB mutations mainly predispose to 215 
extra-adrenal PGLs and to a lesser extent to adrenal PCCs and HNPGLs, while SDHD mutations are 216 
typically associated with multifocal HNPGLs and less frequently with adrenal PCCs and extra-adrenal 217 
PGLs [39]. PGLs are more frequently located in the head and neck region at the carotid bifurcation 218 
(carotid body tumor), along with the vagal nerve, in the jugular foramen and the middle ear space. Less 219 
common sites are close to the larynx, thyroid, urinary bladder and the upper mediastinum [14]. The three 220 
probands identified in this study presented with retroperitoneal or pelvic PGLs. Notably, the 221 
c.334_337delACTG carrier in this study showed HNPGL in the right jugular foramen five years before 222 
entry into our study. In addition, we previously reported on multiple PGL patients with three tumors 223 
around the aorta abdominal and the inferior vena cava [17].  224 
Malignant PCC/PGLs are defined by distant metastases commonly found in the liver, lung, bone, and 225 
lymph nodes. The term “metastatic PCC/PGL” has been used to replace “malignant PCC/PGL” in the 226 
latest WHO endocrine tumors classification [40]. Only a minority of PCC/PGL patients harbor malignant 227 
tumors. Reported proportions of malignant PGL vary considerably between most genotype-phenotype 228 
studies, ranging from 31% to 71.4% in SDHB-mutation carriers to 0% to 22.7% in SDHD-mutation 229 
carriers [41]. Although death can occur within a year of diagnosis, metastatic disease can be stable for 230 
more than 40 years. Detection of metastatic tumors can occur prior to the detection of primary tumors, but 231 
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metastatic lesions also could be discovered more than 50 years after the primary diagnosis [42]. Metastasis 232 
is more commonly associated with primary tumors located in the mediastinum (69%) and the 233 
infradiaphragmatic para-aortic area, including the organ of Zuckerkandl (66%) [43]. In our cohort, 3.4 % 234 
(4/119) presented with malignant tumors at diagnosis. The two SDHB germline mutation carriers did not 235 
present with metastases, but a literature review suggests that patients with such mutations may present with 236 
metastases in the neck, lung, mediastinum, abdomen and pelvic region. Rare cases of metastatic HNPGLs 237 
have been described within SDHD mutation carriers and their estimated prevalence is 0–10% [39]. So far, 238 
metastatic lesions have not been recorded in c.334_337delACTG carriers. 239 
SDH-deficient renal carcinoma defined by loss of SDHB expression represents a distinct and rare renal 240 
neoplasm subtype [9], showing a strong correlation with germline SDH mutations [44]. Though it is likely 241 
that not all SDHB IHC-negative tumors will carry SDH mutations, IHC remains a phenotypic test as well 242 
as an indirect genotypic test. Though our patients presented with no signs of renal cancer, it is important to 243 
note the elevated life-long risk of PGL and renal cancer co-occurrence in such patients. At the same time, 244 
it is worthwhile to exclude the possibility of other tumors like GIST, pancreatic neuroendocrine tumor, 245 
pituitary adenoma, and pulmonary chondroma. 246 
In conclusion, we presented three gene-specific germline mutations in SDH genes and their relevant 247 
phenotypes. Findings of our study suggest that the incidence of c.343C>T mutations is likely 248 
underestimated in PCC/PGL patients. Patients with the SDHB mutation, c.541-2A>G, had severe and 249 
complicated phenotypes. The c.334_337delATCG SDHD mutation appears to influence SDHB expression 250 
and associates with a more aggressive phenotype. These specific cases add to our knowledge of PCC/PGLs 251 
and may help with the genetic counseling of patients. Genotype-tailored treatment options, follow-up and 252 
preventive care are warranted.  253 
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Figure Legends: 404 
Figure 1. Histopathological features of the tumors. (A, proband 1; B, proband 2; C, proband 3; stained with 405 
H&E ×200).  406 
Figure 2. Abdominal CT or MRI scans of the probands. (A and D) Coronal (A) and axial (D) CT images of 407 
the 5.1 × 3.4 cm retroperitoneal mass between the aorta and inferior vena cava in proband 1; (B and E) 408 
Coronal (B) and axial MRI (E) images of the 3× 2× 2 cm retroperitoneal para-aorta mass in proband 2; (C 409 
and F) Coronal (C) and axial (F) images of the 2.9 × 2.7cm mass located at the bifurcation of the 410 
abdominal aorta in proband 3. 411 
Figure 3. Gene sequencing reveals mutations in the SDHB and SDHD gene. (A) The mutation c.343C>T 412 
in proband 1, (B) The mutation c.541-2A>G in proband 2. (C) The mutation c.334_337delACTG in 413 
proband 3. 414 
Figure 4. IHC staining for SDHB and SDHD in the tumor tissues. (A-D) IHC staining for SDHB in the 415 
GIST positive control tissue (A), in PCC/PGL tissue of proband 1 (B), 2 (C), and 3 (D). (E-H) IHC 416 
staining for SDHD in the tumor tissue of the sporadic PGL patient (used as positive control tissue, E), in 417 
PCC/PGL tissue of proband 1 (F), 2 (G), and 3 (H). Magnification ×200. 418 
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Figure 1. Histopathological features of the tumors. (A, proband 1; B, proband 2; C, proband 3; stained with 
H&E ×200)  
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Figure 2. Abdominal CT or MRI scans of the probands. (A and D) Coronal (A) and axial (D) CT images of the 
5.1 × 3.4 cm retroperitoneal mass between the aorta and inferior vena cava in proband 1; (B and E) 
Coronal (B) and axial MRI (E) images of the 3× 2× 2 cm retroperitoneal para-aorta mass in proband 2; (C 
and F) Coronal (C) and axial (F) images of the 2.9 × 2.7cm mass located at the bifurcation of the abdominal 
aorta in proband 3.  
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Figure 3. Gene sequencing reveals mutations in the SDHB and SDHD gene. (A) The mutation c.343C>T in 
proband 1, (B) The mutation c.541-2A>G in proband 2. (C) The mutation c.334_337delACTG in proband 3.  
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Figure 4. IHC staining for SDHB and SDHD in the tumor tissues. (A-D) IHC staining for SDHB in the GIST 
positive control tissue (A), in PCC/PGL tissue of proband 1 (B), 2 (C), and 3 (D). (E-H) IHC staining for 
SDHD in the tumor tissue of the sporadic PGL patient (used as positive control tissue, E), in  PCC/PGL tissue 
of proband 1 (F), 2 (G), and 3 (H). Magnification ×200.  
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Table 1.  Characteristics of patients carrying SDH gene mutations 
 Patient one Patient two Patient three 
Gene SDHB SDHB SDHD 
Gender/Age Male/14 Male/32 Female/45 
Site Post-caval Para-aortic Bifurcation of abdominal aorta 
Size(cm) 5.1*3.4 3*2*2 2.9*2.7 
Diagnosis PGL PGL Hereditary PGL 
Headache + _ _ 
Palpitation + _ + 
Diaphoresis + _ _ 
Dizziness _ _ + 
Nausea + _ + 
HypertensionÄmmHgÅ 208/156 160/100 154/75 
Nucleotide change c.343C>T c.541-2A>G c.334_337delACTG 
Mutation P.Arg115Ter IVS5-2A>G p.Asp113Metfs*21 
Mutation type detrimental mutation pathogenic pathogenic 
Heterozygous  Het Het  Het 
Aldosterone (erect 
position/decubitus; 
ng/ml) 
 
0.254/0.257 
 
NA 
 
0.13/0.14 
Cortisol 
(8h;16h;24h;ng/ml) 
NA NA 215/261/102 
Increased E NA NA NA 
Increased NE NA 1.89ng/ml NA 
VMA 72.0µmol/24h 178.36µmol/24h — 
MN 5.1µmol/24h — — 
PTH 41.04pg/ml NA NA 
17-OH 13.5µmol/24h — — 
17-KS 30.2µmol/24h — — 
 
Renin 
 
NA 
35.71uIU/ml;50.38uIU/
ml (2 hours after 
motivated) 
1.08 ng/ml 
0.75 ng/ml 
PRA(erect 
position/decubitus; 
ng/ml) 
 
NA 
 
NA 
 
1.08/0.75 
Angiotensin II (erect 
position/decubitus; 
pg/ml) 
 
NA 
 
NA 
 
39/35 
ARR(erect 
position/decubitus) 
NA NA 12/18 
ACTH 
(8h:16h:24h; pg/ml) 
 
NA 
 
NA 
 
10.30/11.15/9.32 
Other Disease Thyroid Nodule Atrial flutter HNPGL×Renal cyst 
Metastasis — — — 
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Follow-up(months) 76 5 41 
Outcome NED NED NED 
“+” represented existence of this phenotype, “É ” nonexistence; NA=not available; E= 
epinephrine; NE= Norepinephrine; VMA=vanillylmandelic acid; MN=noradrenaline; 
PTH=parathyroid hormone; 17-OH=17-OH-corticosteroid; 17-KS= 17-ketosteroid; PRA=plasma 
renin activity; ARR= Aldosterone Renin ratio; ACTH=Adrenocorticotropic hormone; NED=no 
evidence of disease. 
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